Fate Therapeutics Inc (NAS:FATE)
$ 3.68 0.23 (6.67%) Market Cap: 418.90 Mil Enterprise Value: 111.25 Mil PE Ratio: 0 PB Ratio: 0.99 GF Score: 58/100

Q1 2023 Fate Therapeutics Inc Earnings Call Transcript

May 03, 2023 / 09:00PM GMT
Release Date Price: $6.32 (+6.76%)
Operator

Welcome to the Fate Therapeutics First Quarter 2023 Financial Results Conference Call. (Operator Instructions)

I would now like to introduce Scott Wolchko, President and CEO of Fate Therapeutics.

J. Scott Wolchko
Fate Therapeutics, Inc. - Founder, CEO, President & Director

Thank you. Good afternoon and thanks everyone for joining us for the Fate Therapeutics first quarter 2023 financial results call. Shortly after 4:00 p.m. Eastern Time today, we issued a press release with these results, which can be found on the Investors section of our website under Press Releases. In addition, our Form 10-Q for the year ended March 31, 2023 was filed shortly thereafter and can be found on the Investors section of our website under Financial Information.

Before we begin, I would like to remind everyone that except for statements of historical facts, the statements made by management and responses to questions on this conference call are forward-looking statements under the Safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot